RESUMEN
BACKGROUND/AIM: Triple-negative breast cancer (TNBC) is the most malignant breast cancer subtype with a short survival time and high morality. There is an urgent need for effective indicators able to predict tumor progression and provide reference for adjusting the therapeutic strategy of TNBC. lncRNA semaphorin 3B antisense RNA1-AS1 (SEMA3B-AS1) was previously identified to be correlated with the stemness and autophagy of breast cancer. SEMA3B-AS1's role in TNBC was investigated in the present study, aiming to explore a novel biomarker for the development and prognosis of TNBC. MATERIALS AND METHODS: SEMA3B-AS1 expression was detected in tissue samples from 113 TNBC patients using PCR. The clinical significance of SEMA3B-AS1 was assessed by the Chi-square test and Cox analysis. The in vitro function of SEMA3B-AS1 was investigated by CCK8 and Transwell assay. Study of molecular mechanism, correlation analysis and dual-luciferase reporter assay were employed to assess the correlation of SEMA3B-AS1 with miR-513c-5p. RESULTS: A significant down-regulation of SEMA3B-AS1 was observed in TNBC, which was related to patient TNM stage, lymph node metastasis, and Ki67 levels. SEMA3B-AS1 down-regulation indicated patients' adverse prognoses and served as an independent prognostic factor. In vitro, SEMA3B-AS1 suppressed the stemness, proliferation, and metastasis of TNBC cells. Moreover, SEMA3B-AS1 negatively regulated miR-513c-5p, which could reverse the inhibitory effects of SEMA3B-AS1 on TNBC cells. CONCLUSION: SEM3B-AS1 indicates the severity of TNBC patients and regulates tumor progression via modulating miR-513c-5p.
Asunto(s)
MicroARNs , ARN Largo no Codificante , Semaforinas , Neoplasias de la Mama Triple Negativas , Humanos , MicroARNs/genética , MicroARNs/metabolismo , Neoplasias de la Mama Triple Negativas/patología , ARN Largo no Codificante/genética , ARN Largo no Codificante/metabolismo , Línea Celular Tumoral , Proliferación Celular/genética , Regulación Neoplásica de la Expresión Génica , Movimiento Celular/genética , Glicoproteínas de Membrana/genética , Semaforinas/genética , Semaforinas/metabolismoRESUMEN
It has been reported that SEMA3B-AS1 is a tumor-suppressive lncRNA in gastric cardia adenocarcinoma. We explored the possible involvement of SEMA3B-AS1 in hepatocellular carcinoma (HCC). We found that SEMA3B-AS1 was downregulated in HCC tissues compared with noncancer tissues and was not affected by hepatitis B virus (HBV) and hepatitis C virus (HCV) infections. In addition, SEMA3B-AS1 expression was not affect by cancer development, and low SEMA3B-AS1 levels were closely correlated with poor survival. SEMA3B-AS1 in HCC tissues was inversely correlated with microRNA (miR)-718 and positively correlated with PTEN. In HCC cells, SEMA3B-AS1 overexpression resulted in upregulated, while miR-718 overexpression resulted in downregulated phosphatase and tensin homolog (PTEN) expression. In addition, miR-718 overexpression attenuated the effects of SEMA3B-AS1 overexpression. SEMA3B-AS1 and PTEN overexpression resulted in a reduced proliferation rate of HCC cells, while miR-718 overexpression resulted in an increased rate. In addition, miR-718 overexpression attenuated the effects of SEMA3B-AS1 overexpression. Therefore, miR-718 may mediate the indirect interaction between lncRNA SEMA3B-AS1 and PTEN to regulate the proliferation of hepatocellular carcinoma cells.